Indivior a 'buy' for Citi on likely monthly opioid launch

Oliver Haill WebFG News | 08 Nov, 2017 15:02 | | |

shot injection arm medical drug pharmaceutical

Indivior

376.80

17:17 17/11/17
-0.05%
-0.20
  • 19,797.83
  • -0.26%-52.17
  • Max: 19,861.05
  • Min: 19,747.99
  • Volume: 0
  • MM 200 : n/a
17:18 17/11/17
  • 12,437.76
  • -0.89%-111.94
  • Max: 12,549.70
  • Min: 12,398.85
  • Volume: 0
  • MM 200 : n/a
17:18 17/11/17
  • 4,102.67
  • -0.12%-4.73
  • Max: 4,116.61
  • Min: 4,089.64
  • Volume: 0
  • MM 200 : n/a
17:18 17/11/17
  • 4,051.78
  • -0.11%-4.62
  • Max: 4,065.06
  • Min: 4,039.36
  • Volume: 0
  • MM 200 : n/a
17:25 17/11/17

Indivior is likely to gain approval from US regulators for its monthly treatment for opioid addiction, which should eventually lift company sales north of $1bn, said Citigroup on Wednesday as it upgraded the stock to 'buy' from 'neutral'.

Citi, which hiked its share price target to 490p from 280p, said the safety and compliance benefits of the RBP-600 monthly buprenorphine injection should support a peak market share estimate of 15%, with launch expected in February 2018 if it gains approval from the Food & Drug Administration by the end of this month.

Competition for RBP-600 is expected to come from a monthly depot from Camarus launched in a similar timeframe, but Citi believe Indivior’s "strong track record of brand building and sales and marketing competence should prove to be a decisive factor".

Next year is an important one for the company, with generic rivals to its Suboxone film expected from April if not before, while a deadline for approval of Invidior's RBP-7000 monthly risperidone for treatment of schizophrenia to come in the third quarter.

Litigation also looms over Indivior somewhat, with Dr Reddy’s needing to attain approval for its generic version of Suboxone, expected in the first quarter, while a ruling on the ANDA court case versus Alvogen also in that quarter.

Indivior has appealed against the Dr Reddy’s ruling, which leads to further uncertainty around timing, but with Indivior launching the RBP-6000 line extension at attractive pricing, Citi sees this as protecting the franchise.

More news

17 Nov Europe close: Stocks slip going into the weekend

Stocks reversed early gains as investors opted to play it safe going into the weekend and the euro edged a tad higher on the back of the political gyrations on Capitol Hill.

17 Nov Europe open: Stocks start slightly higher, analysts wary

Stocks have started the morning trading slightly higher, tracking overnight gains on Wall Street but analysts are worried about buying into Thursday's bounce.

17 Nov London close: Stocks finish week on down note

London's top flight index slipped on Friday, but managed to finish well-off its lows of the session despite renewed Brexit angst as the pound gave back early gains.

17 Nov Kingfisher gets RBC upgrade as 'reasons to be cheerful' in France

DIY retailer Kingfisher has more "reasons to be cheerful" thanks to an improving French outlook, analysts at RBC Capital Markets said on Friday, while clothes seller Supergroup remains "compelling" but its shares have gained a lot in recent weeks.

17 Nov NAV on the rise as Alpha Real Estate Trust turns focus to build-to-rent market

Real estate investment group Alpha Real Trust saw its net asset value (NAV) rise in its first half of trading as it moved to make further investments in build-to-rent projects.

17 Nov Pacific Industrial & Logistics completes sale of Bedford asset

Industrial and logistics-focussed real estate investment trust Pacific Industrial & Logistics has completed the sale of an asset located at Hammond Road, Bedford, for a total consideration of £5.8m, it announced on Friday.

17 Nov DP Poland cuts ribbon on 50th Polish Domino's store

DP Poland, which holds the exclusive master franchise for the Domino’s Pizza brand in Poland, celebrated the opening of its 50th location in the country on Friday.

17 Nov Mercia Technologies makes new investment into Aston EyeTech

National investment group Mercia Technologies has made a new direct investment into Aston EyeTech - a spinout from Aston University, Birmingham - which has developed a range of proprietary hardware and software products in ocular care, it announced on Friday.

17 Nov SimiGon receives final approval for $2m Israeli Air Force order

Modelling, simulation and training solutions provider SimiGon has now received final regulatory approval for a $2m purchase order received from the Israeli Air Force, initially announced on 20 June 2016, it confirmed on Friday.

17 Nov Agriterra losses grow after 'subdued' interest in corn products

Agricultural investment group Agriterra saw losses widen in the first half of its trading year as subdued demand for its maize flour products slashed revenues by more than a third.